Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants.

Authors:
Hans Proquitté Thekla Dushe Hannes Hammer Mario Rüdiger Gerd Schmalisch Roland R Wauer

Respir Med 2007 Jan 15;101(1):169-76. Epub 2006 May 15.

Clinic of Neonatology (Charité Campus Mitte), Humboldt-University Berlin, Berlin.

Introduction: Natural surfactants have been shown to be superior to synthetic surfactants in the treatment of neonatal respiratory distress syndrome (RDS). In Germany, Alveofact (A) and Curosurf (C) are the most frequently used natural surfactant preparations. The aim of this retrospective, observational study was to compare the effects of A and C on gas exchange and outcome in premature infants.

Methods: During a 5-year period in our neonatal intensive care unit (NICU), 187 premature infants were treated with surfactant, with 82 receiving A and 105 receiving C. We recorded F(I)O(2) and gas exchange (PaO(2)/F(I)O(2) ratio, PaCO(2), SaO(2)) during the first 72h after surfactant application and the incidence of outcome parameters at day 28 (bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH grade III or IV), patent ductus arteriosus (PDA), pneumothorax, necrotizing enterocolites (NEC) and death). The differences between the patient groups were assessed by ANOVA or the calculation of relative risks. Bonferroni correction was used for multiple comparisons.

Results: There were no statistically significant differences between infants treated with A and C in mean gestational age (28.4 vs. 28.4 weeks), birth weight (1210 vs.1258 g) and time of first surfactant application (60 vs. 90 min postnatal). We observed no significant between group differences in course of F(I)O(2) and blood gases, or in incidence at day 28 of BPD (41.7% vs. 42.8%), IVH III/IV (18.3% vs. 14.3%), pneumothorax (9.8% vs. 4.8%), PDA (23.2% vs. 21.9%), PVL (7.3% vs. 9.5%) and death (17% vs. 17.1%). There were also no statistically significant differences in the subgroup of infants <28 weeks. The lower incidence of NEC in A compared with C (1.2% vs. 10.5%, P=0.01) was not statistically significant after Bonferroni correction.

Conclusion: Independent of gestational age no significant difference in the clinical efficacy of A and C was observed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2006.03.033DOI Listing
January 2007

Publication Analysis

Top Keywords

alveofact curosurf
8
natural surfactants
8
gas exchange
8
respiratory distress
8
premature infants
8
distress syndrome
8
surfactant application
8
infants treated
8
statistically differences
8
observational study
8
study compare
8
differences patient
4
death differences
4
differences
4
nec death
4
pneumothorax necrotizing
4
necrotizing enterocolites
4
enterocolites nec
4
patient groups
4
groups assessed
4

Similar Publications

The Inhibitory Effect of Curosurf and Alveofact on the Formation of Neutrophil Extracellular Traps.

Authors:
Annabell Schulz Laia Pagerols Raluy Jan Philipp Kolman Ingo Königs Magdalena Trochimiuk Birgit Appl Konrad Reinshagen Michael Boettcher Julian Trah

Front Immunol 2020 19;11:582895. Epub 2021 Jan 19.

Department of Pediatric Surgery, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.

Background: Neutrophil extracellular traps (NETs) are a defense mechanism in which neutrophils cast a net-like structure in response to microbial infection. NETs consist of decondensed chromatin and about 30 enzymes and peptides. Some components, such as neutrophil elastase (NE) and myeloperoxidase (MPO), present antimicrobial but also cytotoxic properties, leading to tissue injury. Read More

View Article and Full-Text PDF
January 2021
Similar Publications

Evaluation of the Acute Pulmonary Response to Poractant Alfa and Bovactant Treatments in Lung-Lavaged Adult Rabbits and in Preterm Lambs with Respiratory Distress Syndrome.

Authors:
Francesca Ricci Fabrizio Salomone Elke Kuypers Daan Ophelders Maria Nikiforou Monique Willems Tobias Krieger Xabier Murgia Matthias Hütten Boris W Kramer Federico Bianco

Front Pediatr 2017 31;5:186. Epub 2017 Aug 31.

Department of Preclinical Pharmacology, R&D, Chiesi Farmaceutici S.p.A., Parma, Italy.

Background: Poractant alfa (Curosurf) and Bovactant (Alveofact) are two animal-derived pulmonary surfactants preparations approved for the treatment of neonatal respiratory distress syndrome (nRDS). They differ in their source, composition, pharmaceutical form, and clinical dose. How much these differences affect the acute pulmonary response to treatment is unknown. Read More

View Article and Full-Text PDF
August 2017
Similar Publications

Comparison of the Efficacy of Three Natural Surfactants (Curosurf, Survanta, and Alveofact) in the Treatment of Respiratory Distress Syndrome Among Neonates: A Randomized Controlled Trial.

Authors:
Mirhadi Mussavi Keyvan Mirnia Khairollah Asadollahi

Iran J Pediatr 2016 Oct 25;26(5):e5743. Epub 2016 Jul 25.

Department of Social Medicine, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, IR Iran.

Background: Although several different types of natural surfactants are available, including Alveofact, Curosurf, and Survanta, the preferred type and the magnitude of their effects are unknown.

Objectives: This study was designed to compare the effects of these three surfactants on the gas exchange and clinical outcomes of neonates with respiratory distress syndrome (RDS).

Methods: This triple-blind randomized clinical trial studied all preterm neonates ≤ 37 weeks with RDS who were admitted to the neonatal intensive care unit (NICU) of Taleghani hospital (Tabriz, Iran) between 2012 and 2013. Read More

View Article and Full-Text PDF
October 2016
Similar Publications

Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials.

Authors:
Liang Zhang Hong-Yi Cao Shuang Zhao Li-Jie Yuan Dan Han Hong Jiang Song Wu Hong-Min Wu

Pulm Pharmacol Ther 2015 Oct 18;34:46-54. Epub 2015 Aug 18.

Department of Neonatology, The First Affiliated Hospital of China Medical University, No. 155 Nan Jing Northern Street, Shenyang 110001, PR China. Electronic address:

Background: The utilization of multiple natural and synthetic products in surfactant replacement therapies in treatment of neonatal respiratory distress syndrome (NRDS) prompted us to take a closer looks at these various therapeutic options and their efficacies. The purpose of our study was to evaluate the effects of six exogenous pulmonary surfactants (EPS) (Survanta, Alveofact, Infasurf, Curosurf, Surfaxin and Exosurf) on mortality rate in NRDS by a network meta-analysis.

Methods: An exhaustive search of electronic databases was performed in PubMed, Ovid, EBSCO, Springerlink, Wiley, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang and VIP databases (last updated search in October 2014) to retrieve randomized controlled trials (RCTs) relevant to our study topic. Read More

View Article and Full-Text PDF
October 2015
Similar Publications

Pulmonary surfactant in the airway physiology: a direct relaxing effect on the smooth muscle.

Authors:
A Calkovska B Uhliarova M Joskova S Franova M Kolomaznik V Calkovsky S Smolarova

Respir Physiol Neurobiol 2015 Apr 10;209:95-105. Epub 2015 Jan 10.

Department of Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia. Electronic address:

Beside alveoli, surface active material plays an important role in the airway physiology. In the upper airways it primarily serves in local defense. Lower airway surfactant stabilizes peripheral airways, provides the transport and defense, has barrier and anti-edematous functions, and possesses direct relaxant effect on the smooth muscle. Read More

View Article and Full-Text PDF
April 2015
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap